Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune.

Published byศุภวิทย์ วอชิงตัน Modified over 5 years ago

Similar presentations

Presentation on theme: "Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune."— Presentation transcript:

1 Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor  Youjin Kim, MD, Chu Hyun Kim, MD, Ho Yun Lee, MD, PhD, Se-Hoon Lee, MD, PhD, Hong Sook Kim, PhD, Sook Lee, MS, Hongui Cha, MS, Sungjun Hong, MS, Kyunga Kim, PhD, Sang Won Seo, MD, PhD, Jong-Mu Sun, MD, PhD, Myung-Ju Ahn, MD, PhD, Jin Seok Ahn, MD, PhD, Keunchil Park, MD, PhD  Journal of Thoracic Oncology  Volume 14, Issue 9, Pages (September 2019) DOI: /j.jtho Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Comparison of overall survival (OS) between patients with hyperprogressive disease (HPD) and patients without HPD. (A) OS according to response by volumetric measurement. (B) OS according to response by the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). (C) Hazard rate plot constructed by using Kaplan-Meier analysis for patients with HPD and patients without HPD. CI, confidence interval; HPDV, patients with HPD assessed by volumetry; non-HPDV, patients without HPD assessed by volumetry; HPDR, patients with HPD assessed by RECIST 1.1; non-HPDR, patients without HPD assessed by RECIST 1.1. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Discrepancy between volumetric measurement of hyperprogressive disease (HPD) according to the Response Evaluation Criteria in Solid Tumors RECIST, version 1.1 (RECIST 1.1). (A) Progression pattern in patients with discrepancy between the two assessment methods. (Left) Patients with HPD assessed by volumetry (HPDV) and patients without HPD assessed by RECIST 1.1 (non-HPDR) (n = 13); (right) patients without HPD assessed by volumetry (non-HPDV) and patients with HPD assessed by RECIST 1.1 (HPDR) (n = 9). (B) Comparison of overall survival between patients with HPD and patients without HPD among patients without HPD when categorized by RECIST 1.1. OS, overall survival; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Genomic alterations associated with hyperprogressive disease (HPD), no HPD (non-HPD), stable disease, and partial response (PR) in anti–programmed death 1/programmed death ligand 1 (PD-L1)–treated patients (16 in patients with HPD assessed by volumetry, 28 in patients without HPD assessed by volumetry, 39 in patients with stable disease, and 27 in patients with a PR). Genes with significantly different mutation patterns between patients with HPD and patients without HPD are presented. Patient characteristics and clinical history are summarized in the top panel. ICI, immune checkpoint inhibitor; TMB, tumor mutation burden; RAF1, Raf-1 proto-oncogene, serine/threonine kinase gene; CDKN2A, cyclin dependent kinase inhibitor 2A gene; STK11, serine/threonine kinase 11 gene; JAK2, Janus kinase 2 gene; MDM2, MDM2 proto-oncogene gene; B2M, beta-2-microglobulin gene; NFE2L2, nuclear factor erythroid 2, like 2 gene; JAK1, Janus kinase 1 gene; BACH1, BTB domain and CNC homolog 1 gene; MDM4, MDM4 regulator of p53 gene; AMP, amplification; DEL, deletion; SNV, single-nucleotide variant; ADC, adenocarcinoma; SQCC, squamous cell carcinoma. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Case of hyperprogressive disease (HPD). (A and B) Before baseline. (C and D) At baseline. (E and F) At first imaging. According to the Response Evaluation Criteria in Solid Tumors RECIST, version 1.1, criteria, the primary lung lesion in the right lower lobe is considered a target lesion (thick arrow). Small, ill-defined lung-to-lung metastases and multiple scattered hepatic and lymph node metastases can be observed. Lesions that harbor significantly different mutation patterns are marked by arrowheads. Appearance of new lesions (black arrows) suggests progression of the disease (not evaluated quantitatively). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune."

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape  Hawazin Faruki,

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape  Hawazin Faruki,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer  Naeyun Choi,

The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer  Naeyun Choi,
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,
Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations  Tae Jung Kim, MD, PhD, Choon-Taek.

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations  Tae Jung Kim, MD, PhD, Choon-Taek.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Similar presentations

Ads by Google